

Regulatory Science in CDRH's Office of Science and Engineering Laboratories

Christopher Scully, PhD

Christopher.Scully@fda.hhs.gov

Division of Biomedical Physics Office of Science and Engineering Laboratories Center for Devices and Radiological Health

June 13, 2019

Disclaimer



The mention of commercial products, their sources, or their use in connection with material reported herein is not to be construed as either an actual or implied endorsement of such products by the Department of Health and Human Services.









Center for Food Safety & Applied Nutrition



Center for Drug Evaluation & Research



Center for Biologics Evaluation & Research



Center for Tobacco Products



Center for Devices & Radiological Health



Center for Veterinary Medicine



National Center for Toxicological Research





- Patients in the U.S. have access to highquality, safe, and effective medical devices of public health importance first in the world.
- The U.S. is the world's leader in regulatory science, medical device innovation and manufacturing, and radiation-emitting product safety.
- U.S. post-market surveillance quickly identifies poorly performing devices, accurately characterizes real-world performance, and facilitates device approval or clearance.
 - Devices are legally marketed in the U.S. and remain safe, effective, and of high-quality.
 - Consumers, patients, their caregivers, and providers have access to understandable science-based information about medical devices and use this information to make health care decisions.



CDRH in Perspective



1900 EMPLOYEES	18k Medical Device Manufacturers	183k Medical Devices On the U.S. Market	
22k /year Premarket	570k Proprietary Brands	1.4 MILLION/year Reports on	
Submissions includes supplements and amendments	25k Medical Device Facilities	adverse events and malfunctions	



CDRH Structure After Reorg Implementation





CDRH Mission



...We provide consumers, patients, their caregivers, and providers with understandable and accessible science-based information about the products we oversee...

We facilitate medical device innovation by advancing regulatory science, providing industry with predictable, consistent, transparent, and efficient regulatory pathways, and assuring consumer confidence in devices marketed in the U.S.



What is Regulatory Science?





Office of Science and Engineering Laboratories

 OSEL is comprised of 155 engineers, physicists, biologists, material scientists, mathematicians...



- Our objective is to:
 - Ensure readiness for innovative technologies
 - Develop test methods and facilitate optimization of devices
 - Deliver timely and accurate decisions for medical devices
 - Create accessible and understandable public health information
 - Through a culture of "4C"s: Customer first, Communication, Collaboration and Consultancy.

OSEL in Perspective



183 FEDERAL EMPLOYEES Up to 180 visiting scientists	140 Projects In 27 Laboratories and Program Areas	400 /year Peer reviewed presentations, articles, and other public disclosures		
2,500k /year	75 Standards and conformity assessment committees	55,000 ft ² Lab facilities		
Premarket Regulatory consults	70% Staff with post graduate degree			

OSEL in Perspective



• Key role in Pre-regulatory phase technology



- AND in translational phase(s)
 - We are developing tools for a more efficient evaluation of new devices





DBP Division Mission



The Division of Biomedical Physics (DBP) participates in the Center's mission of protecting and promoting public health by identifying and investigating the biophysical interactions between medical devices and the human body.



Contact: Zane Arp (<u>Zane.Arp@fda.hhs.gov</u>)

- EMC/wireless/electrical safety
- Neuroscience
- Optical physics
- MRI
- Functional performance and device use
- Cardiac electrophysiology
- Advanced patient monitoring and control
- Biomechanics





16

Advanced Patient Monitoring and Control

Areas of interest: Advances in analytics, automation, and interoperability in safety critical electro-medical equipment

Objective: Investigate and develop novel solutions aimed to assure the safety and effectiveness of medical devices that include advanced patient monitoring, physiological closed-loop control, or interoperable technology

Example research topics:

- Developing performance assessment methods for advanced patient monitoring algorithms
- Evaluating computational models of physiological systems for testing physiological closed-loop controlled medical devices
- Investigating research platforms and engineering methods to explore the safety implications of increasing complexity in the design and use of medical devices

Contacts:

Christopher Scully (<u>Christopher.Scully@fda.hhs.gov</u>) Sandy Weininger (<u>Sandy.Weininger@fda.hhs.gov</u>)









18

FDA



Identify Critical Events Earlier



Applications for Analytics in Patient Monitoring

ease gressio	At-risk po	opulatio	on Symptomatic	Diagnosed	Deteriorating	Shock	
ng Dise Pro	Trauma Infective a	agent	Systemic Inflammatory Response Syndrome	Infected	Septic	Hypotension, unresponsive to fluid resuscitation	
tori s	Continuous monitoring for patient improvement/deterioration						
Monit		Screer	ning Diagnostic	Mor func	nitoring organ	Guiding supportive therapy	

Reducing false alarms and improving measurement performance Predictive analytics for earlier identification of events

- Alarm management determining optimal settings for patients
 - Automatic adjustment of alarm settings by analyzing past patient data
- Signal quality assessment:
 - Signal artifact detection
 - Use of information from multiple signals
 - Identifying false positive and false negative alarm conditions

- Aid in the assessment of patient current and future condition
 - Patient risk / status indices
 - Monitors of patient deterioration
- Computer-aided detection and diagnosis
 - Detect disease signatures in physiologic waveforms
 - Measure and predict future response to therapy
- Feedback variables for physiological closed-loop systems
- Many other possibilities

Application of Analytics & Artificial Intelligence

Creation of Patient Monitoring Databases

Considerations for Predictive Analytics in Patient Monitoring

- Traditionally, physiological measurements evaluated on an individual basis against established reference methods (may be clinical or bench testing)
 - According to consensus standards for many (e.g., IEC 60601-2-47:2012 for ambulatory ECG)
 - Alarms, generally, use thresholds on measurements or detect 'known' patterns in signals
- Considerations for evaluating data-driven algorithms
 - How representative is the patient population that the data is collected from?
 - How to ensure data quality?
 - Does the specific measurement device used to create the database (or settings on the monitor) have a meaningful impact on the data for the algorithm being developed?
 - What are meaningful endpoints and adequate annotation procedures?
 - How to effectively use potentially limited number of critical events for training and testing?

24

AAMI TIR66:2017 Guidance for the creation of physiologic data and waveform databases to demonstrate reasonable assurance of the safety and effectiveness of alarm system algorithms

- Recognized by FDA
- Provides guidance for:
 - Validating novel & intelligent alarm system algorithms
 - Disclosing performance of those systems
- Database requirements
 - Alignment with intended application of the algorithm
 - Population and Study Design
 - Engineering requirements
 - Annotation requirements
 - Archive requirements
- Waveform acquisition and synthesis
 - Data quality
 - Annotation processes
- Application of waveform databases to testing

Medical Device Interoperability

- Designing systems with interoperability as an objective
- Conducting appropriate verification, validation and risk management activities
- Specifying the relevant functional, performance, and interface characteristics in a user available manner such as labeling

Contains Nonbinding Recommendations

Design Considerations and Premarket Submission Recommendations for Interoperable Medical Devices

Guidance for Industry and Food and Drug Administration Staff

> Document issued on: September 6, 2017 The draft of this document was issued on January 26, 2016.

For questions about this document regarding CDRH-regulated devices, email them to: DigitalHealth@fda.hhs.gov.

For questions about this document regarding CBER-regulated devices, contact the Office of Communication, Outreach and Development (OCOD), by calling 1-800-835-4709 or 240-402-8010.

Patient Monitoring Regulatory Science in OSEL/DBP

Use of patient monitoring databases to evaluate predictive alarm algorithms and effects on alarm fatigue

ECG

NOISE

ECG_{SIM}+NOISE

Simulating physiologic signals for efficient use of databases in algorithm design

Computational methods to investigate the effect of noise and motion artifacts on monitor algorithms

Algorithm Development

Algorithm

Evaluation

Non-clinical testing for interoperable monitoring systems to test performance with different physiologic signal acquisition systems

Characterizing Patterns of Indices Leading up to Critical Event

FDA

- Novel index with an alarm system may have a variety of patterns prior to a critical event
- How should performance be evaluated to provide meaningful and understandable information?
 - Performance within clinically relevant time period before event
 - Distribution of warning times
 - Whether the alarm condition is present until event
 - Number of false alarms / event

FDA

Extracting noise from electrocardiogram recordings for robust algorithm testing

- ANSI/AAMI EC57 includes testing ECG analysis algorithms across range of SNRs by applying 3 recorded noise records
- Same noise records used for all devices unclear if these are adequate and representative for novel portable devices

Approach

- Developed method to enable noise component to be extracted from ECG signal
 - Representative noise records can then be added to annotated databases

Contents lists available at ScienceDirect

journal homepage: www.jecgonline.com

A method to extract realistic artifacts from electrocardiogram recordings for robust algorithm testing

Time (sec)

Hazardous Situations for a Physiologic Closed-Loop Controlled Device

Medical Device Evaluation

- Comprehensive evaluation of a marketing application for a therapeutic medical device typically includes valid scientific evidence from some combination of four possible types of models: animal, bench, computational, and human.
- Each model has its strengths and limitations for predicting clinical outcomes.
- Computational evidence has many potential uses for physiologic closed-loop controlled devices

Uses of Modeling for Physiologic Closed-loop Controlled Devices

Model-Based Design

Established field of engineering Enables quantitative assessment of system Analytical stability Transparency Lends itself well to model-based evaluation

Complete In Silico Testing

Ability to produce a variety of physiological conditions (in silico patients) Modularity

Hardware-in-the-Loop Evaluation

Enables real time testing with device hardware Allow for evaluation of worst-case scenarios Stress testing

Scenarios not easy to replicate in clinical setting

Evaluation of Fluid Resuscitation Control Algorithms via a Hardware-in-the-Loop Test Bed

Hossein Mirinejad^{*}, Bahram Parvinian, Margo Ricks, Yi Zhang, Sandy Weininger, Jin-Oh Hahn, and Christopher G. Scully

Challenges for computational testing of physiologic closed-loop controlled devices

- Need physiological models that lend themselves to control system design
 - Need to be simple enough for design of controller but accurate enough to capture the physiology of interest
 - Physiological systems have many mechanisms that are unknown and difficult to model
- Variability in physiological systems from one patient to another, and within patient
 - 747s are manufactured to be similar with similar properties/response
- High degree of cross-coupling between physiological systems
 - cardiovascular-respiratory-renal
- High degree of versatility for a single physiological system
 - Function of respiratory system is for oxygenation and ventilation, but it also helps to cool the body
- How to demonstrate credibility of computational modeling and simulation results in the evaluation of physiologic closed-loop controlled devices?

The ASME V&V 40 standard outlines a framework for making riskinformed determinations as to whether a CM&S is credible for decision-making for a specified context of use.

Box 1: Define Use of Computational Patient Model Box 3: Establish Computational Patient Model in PCLC Development **Credibility Goals** Characterize nominal performance Questions to Consider -Response time Verify system implementation What other evidence will be used to address the use -Stability -Verify actual therapy delivered of the PCLC question? (animal study, clinical study, -Disturbance rejection -Verify operation of fallback modes analytical assessment) What is the consequence of incorrect simulation Assess performance across range of conditions evidence? -Determine worst case performance What phenomena/physiological systems need to be -Identify unsafe patient conditions modeled? What are the sources of uncertainties in the model? Device design evaluation What is the range of input conditions and -Compare control algorithm designs disturbance profiles that will be used for testing? -Characterize influence of therapy and How could the model error influence the device ١. sensor inaccuracies and delays testing? **Box 2: Design Computational Test Strategy** Box 4: Gather Evidence to Support Computational Patient Model Fully Computational / Disturbance Profiles Verification of numerical model Hardware-in-the loop Sensitivity of model output to input parameters Injury patterns Comparison of simulation to experimental results Therapy patterns **Initial Patient Conditions** Animal / clinical model Additional therapies Demographics Initial conditions and disturbance profiles Changes in physiologic state Injury Numbers of test samples Therapy Quantification of uncertainties 3leed Rate Physiological state Error between comparator and model output Applicability of initial patient conditions and disturbance profiles used for model Time assessment to device testing Interpretation Model Simulation of Simulation Credibility Evidence

Evidence

Evidence

published: 26 March 201 doi: 10.3389/fphys.2019.00220 **Credibility Evidence for Computational Patient Models Used**

http://www.commonscience.com/

in Physiology

in the Development of Physiological **Closed-Loop Controlled Devices for Critical Care Medicine**

Bahram Parvinian*, Pras Pathmanathan, Chathuri Daluwatte, Farid Yaghouby, Richard A. Gray, Sandy Weininger, Tina M. Morrison and Christopher G. Scully REVIEV

AI/ML Discussion Paper

Proposed Regulatory Framework for Modifications to Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD)

Discussion Paper and Request for Feedback

"Today, we're announcing steps to consider a new regulatory framework specifically tailored to promote the development of safe and effective medical devices that use advanced artificial intelligence algorithms."

> Dr. Scott Gottlieb, FDA Commissioner April 2, 2019

FDA U.S. FOOD & DRUG Device

Christopher Scully, Biomedical Engineer <u>Christopher.Scully@fda.hhs.gov</u> Division of Biomedical Physics Office of Science and Engineering Labs

Center for Devices and Radiological Health

Zane Arp, Division Director Zane.Arp@fda.hhs.gov

Division of Biomedical Physics Office of Science and Engineering Labs Center for Devices and Radiological Health